AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01055847 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline Placebo
Study NCT02534571 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endoscopic Application of a Hemostatic Powder TC-325
Description: Endoscopic Application of a Hemostatic Powder TC-325 \<=150g once
Study NCT02534571 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hemo-clipping
Description: Hemo-clipping \<=20 clips
Study NCT02534571 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epinephrine
Description: epinephrine injection endoscopically \<20 mls
Study NCT02534571 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: thermo-coagulation
Description: contact thermo-coagulation \< = 4 pulses
Study NCT03197753 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laryngeal mask airway
Description: Laryngeal mask airway
Study NCT03197753 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nasotracheal intubation
Description: Nasotracheal intubation
Study NCT00569023 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: alga Dunaliella bardawil
Description: Each patients will be treated with four capsules daily of Dunaliella bardawil for 90 days.~Alga Dunaliella bardawil containing 15 mg approximately 50% all-trans beta-carotene and 50% 9-cis beta-carotene isomers
Study NCT01055704 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylnaltrexone only
Description: 0.30 mg/kg subcutaneous injection daily
Study NCT01055704 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Codeine only
Description: 30 mg taken orally four times daily for 5 days
Study NCT01055704 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylnaltrexone + codeine
Description: Methylnaltrexone 0.30 mg/kg by subcutaneous injection once daily and codeine 30 mg taken orally four times daily for 5 days
Study NCT01055704 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo + placebo
Description: Placebo subcutaneous injection once daily and placebo taken orally four times daily for 5 days
Study NCT01971151 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exposure therapy
Description: Treatment protocol:~1) preparation consisting of intake and identification of feared movements, activities and situations and their underlying catastrophic beliefs. 2) education, 3)exposure sessions: patients confront threatening situations and behavioral experiments are performed that are targeted at correcting erroneous catastrophic beliefs. 4) homework assignments.
Study NCT01971151 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exposure therapy
Description: Treatment protocol:~1) preparation consisting of intake and identification of feared movements, activities and situations and their underlying catastrophic beliefs. 2) education, 3)exposure sessions: patients confront threatening situations and behavioral experiments are performed that are targeted at correcting erroneous catastrophic beliefs. 4) homework assignments.
Study NCT01038427 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mometasone furoate 50 mcg/actuation nasal spray (Lek Pharmaceuticals)
Description: Mometasone nasal spray administered once daily at a dose of 200 mcg (4 actuations) for 14 days.
Study NCT01038427 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mometasone furoate (Nasonex®) 50 mcg/actuation nasal spray
Description: Mometasone nasal spray administered once daily at a dose of 200 mcg (4 actuations) for 14 days.
Study NCT01038427 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo nasal spray administered once daily (4 actuations) for 14 days.
Study NCT03872245 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Probiotics
Description: The patients will receive Adomelle 1caps/12h during 10 weeks
Study NCT02780271 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: E-communication
Description: 11 months of motivational text messages, emailed newsletters, and access to a website.
Study NCT03872245 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PENS T6
Description: The patients will undergo percutaneous electrical neurostimulation of dermatome T6 weekle, during 10 weeks
Study NCT03872245 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PENS T6
Description: The patients will undergo percutaneous electrical neurostimulation of dermatome T6 weekle, during 10 weeks
Study NCT02825342 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Citalopram
Study NCT01827046 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rt-PA
Description: Up to 9 doses of 1.0 mg of rt-PA will be administered through the catheter that was placed directly into the intracerebral hemorrhage using minimally invasive surgery.
Study NCT00770900 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: montelukast sodium
Description: Asthmatic children and teenagers took montelukast daily for 12 weeks.~Children aged 2-5 years took 4mg tablet of montelukast~Children aged 6-15 years took 5mg tablet of montelukast~Children >15 years took 10mg tablet of montelukast
Study NCT00770900 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: placebo comparator
Description: Asthmatic children and teenagers took Placebo tablet daily for 12 weeks.
Study NCT00329680 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Eicosapentaenoic acid, Gamma-Linolenic Acid and Antioxidant Vitamins
Description: An enteral diet will be given in accordance with the caloric goal calculated by the Harris-Benedict equation x 1.3. The enteral diet will be provided for a period of 7 days or until death OR start of oral diet OR start of parenteral diet OR discharge from the ICU OR decision from the attending physician/family/patient to no longer participate in this clinical study
Study NCT00329680 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Standard ICU enteral diet, isocaloric to the study diet
Description: Patients will receive this diet in a blinded way using the same dose regimen specified previously and used in the study group
Study NCT01670253 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group 1
Description: * 6 hour fast from all solid foods and milk beverages~* 2-hour thirst period before examination (patient may be in the period from 6 to 2 hours before the study drink any kind of clear liquids, ie liquids containing no milk products)~* Approximately 2 hours before the time of examination please drink a glass (about 2 cups) clear sugary liquid - eg lemonade, apple juice, iced tea, soda or the like.
Study NCT03037203 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JZP-110
Description: 75 mg, 150 mg, 300 mg
Study NCT03037203 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT03037203 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01922388 — intervention group
Intervention type: DEVICE
Intervention: Bilateral deep brain stimulation of the subthalamic nucleus
Study NCT02152943 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Given PO
Study NCT02152943 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02152943 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Given PO
Study NCT02152943 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Given IV
Study NCT01788293 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intervention group
Description: Control group will receive per-operative fluid at the discretion of the anesthetist, whereas Intervention group will receive additional hydroxyethylstarch 6% (HES) bolus in order to minimize and maintain PVI below 14 %.~This PVI cut-off value was chosen according to previous reports \[Cannesson et al., 2008; Zimmermann et al., 2010\].~During the postoperative period, both groups were managed by intensivists (in the ICU) and clinicians (in the wards) not involved in the intraoperative management or in data collection. These individuals were not informed of patient allocation.
Study NCT01808677 — intervention group
Intervention type: OTHER
Intervention: Thoracic Reirradiation Registry
Description: Data collected in the registry includes patient characteristics/demographics, disease characteristics, treatment details (radiation, chemotherapy, surgery, etc.), toxicity rates, and survival outcomes.
Study NCT03321253 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nd: YAG laser posterior capsulotomy
Description: Nd: YAG laser posterior capsulotomy
Study NCT01275781 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-AZD9742
Description: 1000 mg intravenous over 2 hours
Study NCT01635023 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD6244 Dosing Period 1
Description: Treatment A, B, or C depending on randomization assignment
Study NCT01635023 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD6244 Dosing Period 2
Description: Treatment A, B, or C depending on randomization assignment
Study NCT01635023 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD6244 Dosing Period 3
Description: Treatment A, B, or C depending on randomization assignment
Study NCT01635023 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD6244 Dosing Period 4
Description: Treatment B
Study NCT01989169 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Study NCT01989169 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Study NCT01989169 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SSP-004184SS
Study NCT02071277 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pressure targeted modes
Description: Intervention involving three different pressure-targeted modes (APRV, BIPAP, and BIPAPassist) each in a random order generated by a computer on one ventilator. Each mode will be studied for 20 minutes.
Study NCT03616496 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neuraceq PET/CT imaging
Description: PET/CT with Neuraceq injection, blood and urine sampling for protein electrophoresis, bone scintigraphy for the three arm (if the exams are present in the patient's medical record and are less than 3 months old, they do not need to be repeated
Study NCT03616496 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neuraceq PET/CT imaging
Description: PET/CT with Neuraceq injection, blood and urine sampling for protein electrophoresis, bone scintigraphy for the three arm (if the exams are present in the patient's medical record and are less than 3 months old, they do not need to be repeated
Study NCT00694109 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mipomersen Sodium
Description: Subcutaneous injection as a single injection directly into the abdomen, thigh, or outer area of the upper arm.
Study NCT00534170 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic (Yakult)
Description: It is a dietary supplement ,65 ml containing 15 billion lactobacillus
Study NCT04351035 — intervention group
Intervention type: PROCEDURE
Intervention: Tumour resection
Description: It is mandatory that patients recieve surgical treatment for pathological diagnosis of CNS tumours in enrolled patients. Surgical resection of tumours could be regarded as total / subtotal / partial resection and biopsy.
Study NCT02280876 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1 - Andrographis paniculata p/st extract
Description: Andrographis paniculata Extract (ApE), Oral tablets 650 mg, with 170 mg. of andrographolides active principles, three times per day, during a total of 365 continuous days.~Other Names:~• ApE tablets, EUROMED Specific. Santiago Chile.
Study NCT02280876 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 2 - Excipients
Description: Placebo 650mg tabs, 2/day, 365 days continuously.~Other Names:~• Excipients tablets EUROMED Specific. Santiago Chile
Study NCT04499612 — intervention group
Intervention type: PROCEDURE
Intervention: Cardiac implantable electronic device implantation.
Description: Patients who have indications will receive cardiac implantable electronic device implantation.
Study NCT02780271 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control
Description: Written guidelines on diet and physical activity for breast cancer survivors, a pedometer to encourage physical activity, and a brief verbal overview of diet and physical activity guidelines for cancer survivors.
Study NCT04499612 — intervention group
Intervention type: PROCEDURE
Intervention: Cardiac implantable electronic device replace.
Description: Patients who have indications will receive cardiac implantable electronic device replace.
Study NCT04499612 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Duplex ultrasound.
Description: Patients will undergo ultrasound examination of the vessels of the upper and lower extremities.
Study NCT02780271 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Written guidelines on diet and physical activity for breast cancer survivors, a pedometer to encourage physical activity, and a brief verbal overview of diet and physical activity guidelines for cancer survivors.
Study NCT03397602 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: standard care + moderate-intensity continuous exercise training
Description: Participants will attend on-site moderate-intensity continuous exercise training two times weekly for 12 weeks.
Study NCT03397602 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: standard care + high-intensity interval training
Description: Participants will attend on-site high-intensity interval training two times weekly for 12 weeks.
Study NCT03021629 — intervention group
Intervention type: OTHER
Intervention: Serum levels of 1a, 25-Dihydroxyvitamin D3 were measured by an enzyme-linked immuno-absorbent assay
Study NCT03529214 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Exposed study site
Description: The study sites will pilot the Team Birth Project designed to improve team communication (between providers, as well as providers and patients). The project includes three key implementation steps that involve: preparing local sites for the implementation of the project; training and coaching on the use of the tools; and sustainment through peer coaching and data feedback. A mixed methods approach will be used to assess acceptability and feasibility, including: (1) clinician surveys and interviews, (2) implementation team focus groups, and (3) patient surveys.
Study NCT04283253 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Robot + TTT exercise
Description: The intervention will be completed 36 visits approximately 3x/week for 12-18 weeks. The training progression will be sequential with 12 visits completed on the wrist robot, followed by 12 visits on the shoulder-elbow robot and completing with 12 visits alternating sessions on the wrist and shoulder-elbow robot. Participants will perform robot training for 45 minutes with each robot followed by 15 minutes of TTT practice to complete their 60 minute intervention session.
Study NCT00843011 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orvepitant
Description: Orvepitant 60 mg, single dose. 2 different formulation. Formulation 2 is administered with and without food.
Study NCT00666159 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tacrolimus ointment
Description: topical
Study NCT00666159 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pimecrolimus cream
Description: topical
Study NCT01290575 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: capsule, Oral, 0.0mg, twice daily, 14 day
Study NCT04499612 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Echocardiography.
Description: Patients will undergo an ultrasound examination of the heart.
Study NCT04499612 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Blood sampling.
Description: Patients will be taken venous blood to determine the studied markers of hemostasis system.
Study NCT02708407 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peritoneal Dialysis
Description: One week after insertion of a PD catheter the intervention group will received a single nightly exchange, using dialysis fluid containing icodextrin; a variable proportion of participants may require a second exchange as directed by the consultant nephrologist as part of routine care. The second exchange would use dialysis fluid containing glucose, not icodextrin. Support and training will be given to each participant by the PD specialist team.
Study NCT03026075 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Motus Cleansing System (MCS)
Description: The MCS enables colon cleansing during standard colonoscopy using a standard colonoscope. The cleansing device, which is attached to the tip of the colonoscope and is connected to an external workstation, generates fluid jets within the colon thus dissolving the feces into small parts. The fecal matter \& fluids are drained through the evacuation pipe of the cleansing device into a collecting reservoir.
Study NCT00972322 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8245
Description: MK-8245 50 mg twice daily for 28 days
Study NCT00972322 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: placebo
Description: matching placebo to MK-8245 twice daily for 28 days
Study NCT02334579 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: CyberKnife Stereotactic Radiosurgery
Description: Five treatments given over about one week.
Study NCT01533753 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Description: Gabapentin will be administered orally at a starting dose of 300mg at bedtime (titration encouraged to desired effect and tolerability per treating physician). Maximum dose allowed will be 300mg three times a day. One cycle is defined as 28 +/- 7 days.
Study NCT01533753 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venlafaxine
Description: Venlafaxine will be administered orally at the starting dose of 37.5mg daily (titration allowed to desired effect and tolerability per treating physician). Maximum dose allowed will be 75mg per day. One cycle is defined as 28 +/- 7 days.
Study NCT00566189 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Roux-en-Y Bypass Gastroplasty
Description: Under open laparotomy, a stomach section separates a 80-ml proximal gastric pouch. A jejunum section below Treitz's Angle creates an excluded gastrobiliopancreatic limb of 150cm. A Roux-in-Y retrocolic anastomosis of the alimentary limb promotes the continuity between the gastric pouch and the jejunum and a silastic ring reduces the pouch outlet.The anastomosis of the excluded limb is done 100cm below the silastic ring.
Study NCT04004689 — intervention group
Intervention type: OTHER
Intervention: 2 times : 6-minute stepper test with a rest of 20min between each test.
Description: Patients will perform two 6-minute stepper tests separated by a rest period of at least 20 minutes. The second test will begin when the heart rate and the transcutaneous oxygen saturation values will be returned to baseline values. Standardization of the instructions for the test will be based on the actual guidelines for the 6-minute walk test.~The test will be performed in an isolated room in order to avoid noise or external stimuli which can affect performance. The stepper will be placed near a door and the patient was allowed to put a hand on it if out of balance or exhausted. The height of the step will be fixed to 20 cm. A step was defined as the rise and lowering of one foot. The patient was informed of the time each minute. No other encouragement was given. Heart rate and transcutaneous oxygen saturation will be continuously recorded by a pulse oximetry.
Study NCT00218270 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tobacco free snuff
Description: Tobacco free snuff
Study NCT00218270 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tobacco free snuff
Description: Tobacco free snuff
Study NCT00271206 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Progesterone
Description: compared to placebo
Study NCT00271206 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: sugar pill
Description: Compared to progesterone
Study NCT01008800 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Communication
Description: The Center-Based classroom intervention focuses on providing children with an invigorating, motivating learning environment in which emerging skills and knowledge are skillfully brought to a higher level of maturity, integrated with existing abilities, and used functionally. Providing an enriched environment with toys, structured learning, and opportunities for ongoing engagement week may offer the children experiences that they would not otherwise have (Ramey \& Ramey, 1998). Parent training sessions will focus on strategies aimed at improving child social engagement and communication and on topics related to autism characteristics, learning styles, interventions, and resources.
Study NCT01008800 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Social communication
Description: Parent training sessions will focus on teaching parents strategies for enhancing their child's social engagement and communication. Since parents will be using these strategies across all activities throughout the day, there is an increased likelihood of generalization. For parents of minority and underserved children, this may be the first exposure to responsive interaction strategies (Rudy \& Grusec, 2001).